InoCells provides a unique stem cell therapy and banking to rejuvenate the ovary of infertile patients whose ovaries have low quality and quantity of eggs. InoCells provide this patient population a high chance to become pregnant with their own biological child. Currently the only alternative option is donation or adoption.

Our patient population is around 30% of IVF cycles which is increasing in size due to factors such as late pregnancy. InoCells therapy is built on 10 years of R&D. Regulatory & clinical trials for our therapy have been previously approved outside the European Market.

InoCells innovation is patent pending at European Patent Office (EPO). We are setting up our manufacturing in The Netherlands through Brightlands ecosystem. This provides us close proximity to the Dutch, Germany, French & Belgian Markets. It also enables us to perform clinical trials and obtain regulatory approvals to access the European market. Our therapy will be provided as a service to hospitals & IVF centers.

InoCells consists of high-profile scientist with decades of experience in IVF, Stem Cell therapy, pharmaceutics and drug development. Prior collaboration & work with major instituted such as Amsterdam Medical Center (AMC) by InoCells scientists is one of our strongest pillars in The Netherlands. AMC is the guide in infertility in The Netherlands.